Expanded Treatment Options in the Adjuvant Therapy of Colon Cancer: Implications for Oncology Nurses

Pamela Hallquist Viale

ONF 2006, 33(1), 81-90. DOI: 10.1188/06.ONF.81-90

Purpose/Objectives: To review the role of adjuvant therapy in the treatment of patients with colon cancer.

Data Sources: Published articles, Internet sources, and books.

Data Synthesis: Colon cancer is a very common cancer in men and women. Chemotherapy, consisting primarily of 5-fluorouracil, has been used to treat colon cancer since the 1950s, but additional effective agents against metastatic disease now are available. The options for adjuvant chemotherapy have increased dramatically. Ongoing studies are evaluating the role of biologics in adjuvant therapy of colon cancer.

Conclusions: Use of oxaliplatin in the adjuvant setting has further defined exciting new therapy options for patients with colon cancer.

Implications for Nursing: Oncology nurses caring for patients with colon cancer should be aware of new changes in therapy options. Although the addition of new therapies increases the tools in the drug arsenal for the common disease, management of toxicities of therapy is crucial as well. This article reviews changes in therapy options and toxicity management, including discussion of key issues for oncology nurses in the care of patients with colon cancer.

Jump to a section

    References

    Allen, W.L., & Johnston, P.G. (2005). Role of genomic markers in colorectal cancer treatment. Journal of Clinical Oncology, 20, 4545-4552.

    Andre, T., Boni, C., Mounedji-Boudiaf, L., Navarro, M., Tabernero, J., Hickish, T., et al. (2004). Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. New England Journal of Medicine, 350, 2343-2351.

    Andre, T., & de Gramont, A. (2004). An overview of adjuvant systemic chemotherapy for colon cancer. Clinical Colorectal Cancer, 4(Suppl. 1), S22-S28.

    Arora, A., & Potter, J. (2003). Older patients with colon cancer: Is adjuvant chemotherapy safe and effective? Journal of the American Geriatrics Society, 51, 567-569.

    Backes, W.L. (2001). Prodrugs. Clinical Journal of Oncology Nursing, 5, 35.

    Benson, A.B., III, Ajani, J.A., Catalano, R.B., Engelking, C., Kornblau, S.M., Martenson, J.A., Jr., et al. (2004). Recommended guidelines for the treatment of cancer treatment-induced diarrhea. Journal of Clinical Oncology, 22, 2918-2926.

    Benson, A.B., III, Schrag, D., Somerfield, M.R., Cohen, A.M., Figueredo, A.T., Flynn, P.J., et al. (2004). American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. Journal of Clinical Oncology, 22, 3408-3419.

    Cascinu, S., Catalano, V., Piga, A., Mattioli, R., Marcellini, M., Pancotti, A., et al. (2003). The role of levamisole in the adjuvant treatment of stage III colon cancer patients: A randomized trial of 5-fluorouracil and levamisole versus 5-fluorouracil alone. Cancer Investigation, 21, 701-707.

    Cassidy, J., Scheithauer, W., McKendrick, J., Kroning, H., Nowacki, M.P., Seitz, J.F., et al. (2004). Capecitabine (X) vs bolus 5-FU/leucovorin (LV) as adjuvant therapy for colon cancer (the X-ACT study): Efficacy results of a phase III trial [Abstract 3509]. Proceedings of the American Society of Clinical Oncology, 22, 247s.

    Coyle, C., & Wenhold, V. (2001). Painful blistered hands and feet. Clinical Journal of Oncology Nursing, 5, 230-232.

    Di Costanzo, F., Sobrero, A., Gasperoni, S., Dogliotti, L., Frassineti, L., Falcone, A., et al. (2003). Adjuvant chemotherapy in the treatment of colon cancer: Randomized multicenter trial of the Italian National Intergroup of Adjuvant Chemotherapy in Colon Cancer (INTACC). Annals of Oncology, 14, 1365-1372.

    Durand, J.P., Brezault, C., & Goldwasser, F. (2003). Protection against oxaliplatin acute neurosensory toxicity by venlafaxine. Anticancer Drugs, 14, 423-425.

    Figueredo, A., Charette, M.L., Maroun, J., Brouwers, M.C., & Zuraw, L. (2004). Adjuvant therapy for stage II colon cancer: A systematic review from the Cancer Care Ontario Program in Evidence-Based Care's Gastrointestinal Cancer Disease Site Group. Journal of Clinical Oncology, 22, 3395-3407.

    Gamelin, L., Boisdron-Celle, M., Delva, R., Guerin-Meyer, V., Ifrah, N., Morel, A., et al. (2004). Prevention of oxaliplatin-related neurotoxicity by calcium and magnesium infusions: A retrospective study of 161 patients receiving oxaliplatin combined with 5-fluorouracil and leucovorin for advanced colorectal cancer. Clinical Cancer Research, 10(12, Pt. 1), 4055-4061.

    Goetz, M.P., & Grothey, A. (2004). Developments in combination chemotherapy for colorectal cancer. Expert Review of Anticancer Therapy, 4, 627-637.

    Greene, F.L., Page, D.L., Fleming, I.D., Fritz, A., Balch, C.M., Haller, D.G., et al. (Eds.). (2002). AJCC cancer staging manual (6th ed.). New York: Springer-Verlag.

    Grem, J. (2004). Adjuvant therapy for colon cancer: A historical perspective. Journal of the National Cancer Institute, 96, 1116-1117.

    Haller, D.G., Catalano, P.J., Macdonald, J.S., & Mayer, R.J. (1998). Fluoro-uracil (FU), leucovorin (LV) and levamisole (LEV) adjuvant therapy for colon cancer: Five-year final report of INT-0089 [Abstract 982]. Retrieved April 16, 2005, from http://www.asco.org/ac/1,1003,_12-002643-00_18-0031-00_19-0013235,00.asp

    Hickish, T., Boni, C., Tabernero, J., Clingan, P., Colucci, G., Nowacki, M., et al. (2004). Oxaliplatin/5-fluorouracil/leucovorin in stage II and III colon cancer: Updated results of the international randomized "MOSAIC" trial [Abstract 211]. Proceedings of the American Society of Clinical Oncology Gastrointestinal Cancers Symposium, 24, 105.

    Hoff, P.M., & Pazdur, R. (2004). Progress in the development of novel treatments for colorectal cancer. Oncology, 18, 705-708.

    Jemal, A., Murray, T., Ward, E., Samuels, A., Tiwari, R.C., Ghafoor, A., et al. (2005). Cancer statistics, 2005. CA: A Cancer Journal for Clinicians, 55, 10-30.

    Levin, B., Brooks, D., Smith, R.A., & Stone, A. (2003). Emerging technologies in screening for colorectal cancer: CT colonography, immunochemical fecal occult blood tests, and stool screening using molecular markers. CA: A Cancer Journal for Clinicians, 53, 44-55.

    Mahon, S.M. (2004). Colorectal cancer screening: A review of the evidence. Clinical Journal of Oncology Nursing, 8, 536-540.

    Mayer, R.J. (2004). Two steps forward in the treatment of colorectal cancer. New England Journal of Medicine, 350, 2406-2408.

    Meyerhardt, J.A., & Mayer, R.J. (2005). Systemic therapy for colorectal cancer. New England Journal of Medicine, 352, 476-487.

    Midgley, R.S., & Kerr, D.J. (2000). Adjuvant therapy of colorectal cancer. Hospital Practice, 35(5), 55-62.

    Moertel, C.G., Fleming, T.R., Macdonald, J.S., Haller, D.G., Laurie, J.A., Goodman, P.J., et al. (1990). Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. New England Journal of Medicine, 322, 352-358.

    Mysliwiec, P.A., Brown, M.L., Klabunde, C.N., & Ransohoff, D.F. (2004). Are physicians doing too much colonoscopy? A national survey of colorectal surveillance after polypectomy. Annals of Internal Medicine, 141, 264-271.

    Nagore, E., Insa, A., & Sanmartin, O. (2000). Antineoplastic therapy-induced palmar-plantar erythrodysesthesia ("hand-foot") syndrome. Incidence, recognition and management. American Journal of Clinical Dermatology, 1, 225-234.

    National Cancer Insitute. (2003). Common terminology criteria for adverse events (version 3.0) [NIH publication #03-5410]. Atlanta, GA: Author.

    National Cancer Institute. (2004). Stage III colon cancer. Retrieved October 15, 2004, from http://www.cancer.gov/cancertopics/pdq/treatment/colon/HealthProfessional/page8

    National Comprehensive Cancer Network. (2005). National Comprehensive Cancer Network clinical practice guidelines in oncology: Senior adult oncology—v.1.2005. Retrieved April 15, 2005, from http://www.nccn.org/professionals/physician_gls/PDF/senior.pdf

    National Comprehensive Cancer Network. (2006). National Comprehensive Cancer Network clinical practice guidelines in oncology: Colon cancer—v.2.2005. Retrieved November 12, 2005, from http://www.nccn.org/professionals/physician_gls/PDF/colon.pdf

    Nicum, S., Midgley, R., & Kerr, D.J. (2003). Colorectal cancer. Acta Oncologica, 42, 263-275.

    O'Connell, J.B., Maggard, M.A., & Ko, C.Y. (2004). Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging. Journal of the National Cancer Institute, 96, 1420-1425.

    O'Connell, M.J. (2004). Current status of adjuvant therapy for colorectal cancer. Oncology, 18, 751-758.

    Oliveria, S.A., Yood, M.U., Campbell, U.B., Yood, S.M., & Stang, P. (2004). Treatment and referral patterns for colorectal cancer. Medical Care, 42, 901-906.

    Pickhardt, P.J., Choi, J.R., Hwang, I., Butler, J.A., Puckett, M.L., Hildebrandt, H.A., et al. (2003). Computed tomographic virtual colonoscopy to screen for colorectal neoplasia in asymptomatic adults. New England Journal of Medicine, 349, 2191-2200.

    Poplin, E.A., Benedetti, J.K., Estes, N.C., Haller, D.G., Mayer, R.J., Goldberg, R.M., et al. (2005). Phase III Southwest Oncology Group 9415/Intergroup 0153 randomized trial of fluorouracil, leucovorin, and levamisole versus fluorouracil continuous infusion and levamisole for adjuvant treatment of stage III and high-risk stage II colon cancer. Journal of Clinical Oncology, 23, 1819-1825.

    Rao, S., & Cunningham, D. (2003). Adjuvant therapy for colon cancer in the new millennium. Scandinavian Journal of Surgery, 92, 57-64.

    Reddy, G.K. (2004). Efficacy of adjuvant capecitabine compared with bolus 5-fluorouracil/leucovorin regimen in Dukes C colon cancer: Results from the X-ACT trial. Clinical Colorectal Cancer, 4, 87-88.

    Roche Pharmaceuticals. (n.d.). Xeloda® (capecitabine) tablets. Retrieved January 14, 2005, from http://www.rocheusa.com/products/xeloda

    Saltz, L.B., Niedzwiecki, D., Hollis, D., Goldberg, R.M., Hantel, A., Thomas, J.P., et al. (2004). Irinotecan plus fluorouracil/leucovorin (IFL) versus fluorouracil/leucovorin alone (FL) in stage III colon cancer (Intergroup trial CALGB C89803) [Abstract 3500]. Proceedings of the American Society of Clinical Oncology, 23, 246.

    Sargent, C., & Murphy, D. (2003). What you need to know about colorectal cancer. Nursing 2003, 33, 36-41.

    Sargent, D.J., Goldberg, R.M., Jacobson, S.D., Macdonald, J.S., Labianca, R., Haller, D.G., et al. (2001). A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients. New England Journal of Medicine, 345, 1091-1097.

    Sargent, D.J., Wieand, S., Benedetti, J., Labianca, R., Haller, D.G., Shepherd, L.E., et al. (2004). Disease-free survival (DFS) vs. overall survival (OS) as a primary endpoint for adjuvant colon cancer studies: Individual patient data from 12,915 patients on 15 randomized trials [Abstract 3502]. Proceedings of the American Society of Clinical Oncology, 23, 246.

    Scheithauer, W., McKendrick, J., Begbie, S., Borner, M., Burns, W.I., Burris, H.A., et al. (2003). Oral capecitabine as an alternative to IV 5-fluorouracil-based adjuvant therapy for colon cancer: Safety results of a randomized, phase III trial. Annals of Oncology, 14, 1735-1743.

    Schrag, D., Cramer, L.D., Bach, P.B., & Begg, C.B. (2001). Age and adjuvant chemotherapy use after surgery for stage III colon cancer. Journal of the National Cancer Institute, 93, 850-857.

    Skibber, J.M., Minsky, B.D., & Hoff, P.M. (2001). Cancer of the colon. In V.T. DeVita, S. Heilman, S.A. Rosenberg, & S. Hellman (Eds.), Cancer: Principles and practice of oncology (6th ed., pp. 1216-1319). Philadelphia: Lippincott Williams and Wilkins.

    Smith, R.A., Cokkinides, V., & Eyre, H.J. (2004). American Cancer Society guidelines for the early detection of cancer, 2004. CA: A Cancer Journal for Clinicians, 54, 41-52.

    Sorich, J., Taubes, B., Wagner, A., & Hochster, H. (2004). Oxaliplatin: Practical guidelines for administration. Clinical Journal of Oncology Nursing, 8, 251-256.

    Sundararajan, V., Grann, V.R., Jacobson, J.S., Ahsan, H., & Neugut, A.I. (2001). Variations in the use of adjuvant chemotherapy for node-positive colon cancer in the elderly: A population-based study. Cancer Journal, 7, 213-218.

    Thirion, P., Michiels, S., Pignon, J.P., Buyse, M., Braud, A.C., Carlson, R.W., et al. (2004). Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: An updated meta-analysis. Journal of Clinical Oncology, 22, 3766-3775.

    Timmerman, D. (2001). Capecitabine (Xeloda™). Clinical Journal of Oncology Nursing, 5, 36-37.

    Twelves, C., Wong, A., Nowacki, M.P., Abt, M., Burris, H., III, Carrato, A., et al. (2005). Capecetibine as adjuvant treatment for stage III colon cancer. New England Journal of Medicine, 352, 2696-2704.

    Van Cutsem, E., Labianca, R., Hossfeld, D., Bodoky, G., Roth, E., Aranda, E., et al. (2005). Randomized phase III trial comparing infused irinotecan/5-fluorouracil (5-FU/folinic acid (IF) versus 5-FU/FA (F) in stage III colon cancer patients (pts). (PETACC 3) [Abstract 8]. Retrieved November 12, 2005, from http://www.asco.org/ac/1,1003,_12-002636-00_18-0034-00_19-0032649,00.asp

    Viale, P.H., Fung, A., & Zitella, L. (2005). Advanced colorectal cancer: Current treatment and nursing management with economic considerations. Clinical Journal of Oncology Nursing, 9, 541-552.

    Waters, C. (2004). Colorectal cancer: Drug treatment. Hospital Pharmacist, 11, 179-192. Retrieved April 16, 2005, from http://www.pharmj.com/pdf/hp/200405/hp_200405_drugtreatment.pdf

    Wilkes, G.M. (2005). Therapeutic options in the management of colon cancer: 2005 update. Clinical Journal of Oncology Nursing, 9, 31-44.

    Wilkes, G.M., & Barton-Burke, M. (2005). 2005 oncology nursing drug handbook. Sudbury, MA: Jones and Bartlett.

    Williams, N.S., Gaynor, R.B., Scoggin, S., Verma, U., Gokaslan, T., Simmang, C., et al. (2003). Identification and validation of genes involved in the pathogenesis of colorectal cancer using cDNA microarrays and RNA interference. Clinical Cancer Research, 9, 931-946.

    Ychou, M., Raoul, J., Douillard, R., Bugat, L., Mineur, F., Viret, Y., et al. (2005). A phase III randomized trial of LV5FU2 + CPT-11 vs. LV5FU2 alone in adjuvant high risk colon cancer (FNCLCC Accord02/FFCD9802) [Abstract 3502]. Retrieved November 12, 2005, from http://www.asco.org/ac/1,1003,_12-002636-00_18-0034-00_19-0032172,00.asp

    Zaniboni, A., & Labianca, R. (2004). Adjuvant therapy for stage II colon cancer: An elephant in the living room? Annals of Oncology, 15, 1310-1318.